Jed Hubbs, PhD, President and CEO

Jed has recent experience leading an initiative to build a drug discovery program at Codexis, a world leader in pharmaceutical biocatalysis. Before Codexis, Jed was Head of Medicinal Chemistry at Satori Pharmaceuticals, a venture-backed company focused on discovering and developing new Alzheimer’s disease therapies. He began his industrial career as a medicinal chemist at the new Merck site in Boston. Jed has a Ph.D. in organic synthesis from UC Berkeley and completed a NIH postdoctoral fellowship at Harvard University. He is an author or inventor on over 30 peer-reviewed publications and patent applications.

Matthew Toczko, PhD, Secretary and COO

Matthew is an expert in Chemistry, Manufacturing and Controls (CMC) with over 15 years of experience. Prior to co-founding Neurocycle Therapeutics, he spent most of his career working for GlaxoSmithKline in Research Triangle Park, NC. There he served as a CMC technical leader and managed the site's early-phase chemical development group. He has lead both formulation development and chemical development for multiple drug candidates from candidate selection through phase 2. He began his career in GlaxoSmithKline's chemical development group. Matthew holds a Ph.D. in organic chemistry from U.C. Berkeley.

Samer Al-Murrani, Ph.D., M.B.A. – Board Director

With over 25 years in human and animal health industries, Sam has significant executive and fundraising experience. In addition to his role at NCT, he is the CEO of Babylon Bioconsulting LLC; chairs the board of directors at Calidum Inc.; and is a board director at Prommune Inc. He also advises investment banks, and capital management groups in the US and Europe.  Sam holds a Ph.D. in immunology/biochemistry from U. Edinburgh, and an M.B.A. in finance from Baker.